427 related articles for article (PubMed ID: 16716128)
21. Metabolic effects of the atypical antipsychotics.
Wooten J
South Med J; 2007 Aug; 100(8):771-2. PubMed ID: 17713300
[No Abstract] [Full Text] [Related]
22. Toxicology and overdose of atypical antipsychotic medications in children: does newer necessarily mean safer?
Dubois D
Curr Opin Pediatr; 2005 Apr; 17(2):227-33. PubMed ID: 15800418
[TBL] [Abstract][Full Text] [Related]
23. Atypical antipsychotics and pituitary neoplasms in the WHO database.
Doraiswamy PM; Schott G; Star K; Edwards R; Mueller-Oerlinghausen B
Psychopharmacol Bull; 2007; 40(1):74-6. PubMed ID: 17285098
[TBL] [Abstract][Full Text] [Related]
24. Effectiveness of antipsychotic treatments for schizophrenia: interim 6-month analysis from a prospective observational study (IC-SOHO) comparing olanzapine, quetiapine, risperidone, and haloperidol.
Dossenbach M; Erol A; el Mahfoud Kessaci M; Shaheen MO; Sunbol MM; Boland J; Hodge A; O'Halloran RA; Bitter I;
J Clin Psychiatry; 2004 Mar; 65(3):312-21. PubMed ID: 15096069
[TBL] [Abstract][Full Text] [Related]
25. [Antipsychotic-drug-induced hyperprolactinemia: physiopathology, clinical features and guidance].
Besnard I; Auclair V; Callery G; Gabriel-Bordenave C; Roberge C
Encephale; 2014 Feb; 40(1):86-94. PubMed ID: 23928066
[TBL] [Abstract][Full Text] [Related]
26. Healthcare costs associated with treatment of bipolar disorder using a mood stabilizer plus adjunctive aripiprazole, quetiapine, risperidone, olanzapine or ziprasidone.
Jing Y; Kim E; You M; Pikalov A; Tran QV
J Med Econ; 2009 Jun; 12(2):104-13. PubMed ID: 19527195
[TBL] [Abstract][Full Text] [Related]
27. Evidence-based use of second-generation antipsychotics in a state Medicaid pediatric population, 2001-2005.
Pathak P; West D; Martin BC; Helm ME; Henderson C
Psychiatr Serv; 2010 Feb; 61(2):123-9. PubMed ID: 20123816
[TBL] [Abstract][Full Text] [Related]
28. Tardive dyskinesia in the era of typical and atypical antipsychotics. Part 2: Incidence and management strategies in patients with schizophrenia.
Margolese HC; Chouinard G; Kolivakis TT; Beauclair L; Miller R; Annable L
Can J Psychiatry; 2005 Oct; 50(11):703-14. PubMed ID: 16363464
[TBL] [Abstract][Full Text] [Related]
29. Glucose intolerance with atypical antipsychotics.
Hedenmalm K; Hägg S; Ståhl M; Mortimer O; Spigset O
Drug Saf; 2002; 25(15):1107-16. PubMed ID: 12452735
[TBL] [Abstract][Full Text] [Related]
30. Hyperprolactinemia and estimated dopamine D2 receptor occupancy in patients with schizophrenia: analysis of the CATIE data.
Tsuboi T; Bies RR; Suzuki T; Mamo DC; Pollock BG; Graff-Guerrero A; Mimura M; Uchida H
Prog Neuropsychopharmacol Biol Psychiatry; 2013 Aug; 45():178-82. PubMed ID: 23727135
[TBL] [Abstract][Full Text] [Related]
31. Positron emission tomography measurement of dopamine D₂ receptor occupancy in the pituitary and cerebral cortex: relation to antipsychotic-induced hyperprolactinemia.
Arakawa R; Okumura M; Ito H; Takano A; Takahashi H; Takano H; Maeda J; Okubo Y; Suhara T
J Clin Psychiatry; 2010 Sep; 71(9):1131-7. PubMed ID: 20361897
[TBL] [Abstract][Full Text] [Related]
32. Risk of discontinuation of atypical antipsychotic agents in the treatment of schizophrenia.
Mullins CD; Obeidat NA; Cuffel BJ; Naradzay J; Loebel AD
Schizophr Res; 2008 Jan; 98(1-3):8-15. PubMed ID: 17596914
[TBL] [Abstract][Full Text] [Related]
33. Effects of aripiprazole on prolactin levels in subjects with schizophrenia during cross-titration with risperidone or olanzapine: analysis of a randomized, open-label study.
Byerly MJ; Marcus RN; Tran QV; Eudicone JM; Whitehead R; Baker RA
Schizophr Res; 2009 Feb; 107(2-3):218-22. PubMed ID: 19038534
[TBL] [Abstract][Full Text] [Related]
34. [Endocrine side effects among psychiatric patients treated with antipsychotics].
Kovács L; Kovács G
Neuropsychopharmacol Hung; 2006 Jun; 8(2):61-6. PubMed ID: 17073213
[TBL] [Abstract][Full Text] [Related]
35. Olanzapine vs. other antipsychotics in actual out-patient settings: six months tolerability results from the European Schizophrenia Out-patient Health Outcomes study.
Lambert M; Haro JM; Novick D; Edgell ET; Kennedy L; Ratcliffe M; Naber D
Acta Psychiatr Scand; 2005 Mar; 111(3):232-43. PubMed ID: 15701108
[TBL] [Abstract][Full Text] [Related]
36. Optimizing atypical antipsychotic treatment strategies in the elderly.
Katz IR
J Am Geriatr Soc; 2004 Dec; 52(12 Suppl):S272-7. PubMed ID: 15541168
[No Abstract] [Full Text] [Related]
37. The value of atypical antipsychotics in the treatment of schizophrenia.
Jessen LM
Manag Care; 2002 Jul; 11(7 Suppl):8-12; discussion 12-3. PubMed ID: 12181875
[No Abstract] [Full Text] [Related]
38. An open, large, 6-month naturalistic study of outcome in schizophrenic outpatients, treated with olanzapine.
Krzystanek M; Krupka-Matuszczyk I
Hum Psychopharmacol; 2011 Jan; 26(1):81-5. PubMed ID: 23055416
[TBL] [Abstract][Full Text] [Related]
39. Ventricular arrhythmias and cerebrovascular events in the elderly using conventional and atypical antipsychotic medications.
Wang PS; Schneeweiss S; Setoguchi S; Patrick A; Avorn J; Mogun H; Choudhry NK; Brookhart MA
J Clin Psychopharmacol; 2007 Dec; 27(6):707-10. PubMed ID: 18004143
[No Abstract] [Full Text] [Related]
40. Switch to quetiapine in antipsychotic agent-related hyperprolactinemia.
Keller R; Mongini F
Neurol Sci; 2002 Dec; 23(5):233-5. PubMed ID: 12522680
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
